FDA Final Guidance: No Corrections And Removals Reports For Device Enhancements
This article was originally published in The Silver Sheet
Online-Only Content >>> CDRH clarifies that Part 806 recall reports are not necessary for actual device enhancements that do not qualify as a correction or removal.
You may also be interested in...
The draft guidance is an attempt by FDA to reassure companies that they can make an enhancement to a marketed device without worrying that the action will be perceived as a recall. But the effort appears to have increased, rather than alleviated, industry anxieties.
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.